基于GAINED临床试验验证ΔSUVmax用于弥漫性大B细胞淋巴瘤中期PET判读
该研究为GAINED 3期试验的事后分析,在581例弥漫性大B细胞淋巴瘤患者中比较Menton 2011共识判读标准与单纯ΔSUVmax的预后价值。结果显示,基线SUVmax低于10.0时ΔSUVmax会产生假阳性结果,作者推荐除该情况外使用单纯ΔSUVmax评估中期代谢反应。
要点
- PET2时17%(100/581)患者按ΔSUVmax为阴性但按Menton 2011判为阳性,PET4时为8%(49/581)。
- PET2阳性人群中,单纯ΔSUVmax的2年PFS为70%(范围58%-80%),Menton 2011判为阳性者趋向更好为81%(范围72%-87%)。
- 基线SUVmax低于10.0的10例患者按ΔSUVmax均为PET2假阳性,其2年PFS与PET2阴性/PET4阴性者相同。
核心结论
- 作者推荐在弥漫性大B细胞淋巴瘤患者中,除基线SUVmax低于10.0的情况外,使用单纯ΔSUVmax而非Menton 2011标准评估中期代谢反应。
研究设计与样本
- GAINED 3期试验(ClinicalTrials.gov标识NCT01659099)的事后分析,评估PET驱动的巩固治疗策略。
- 对581例患者在免疫化疗2周期(PET2)和4周期(PET4)后行18F-FDG PET/CT实时中心判读,采用Menton 2011标准结合ΔSUVmax(PET2和PET4截断值分别为66%和70%)与Deauville量表。
- 在基线SUVmax低于10.0或中期残留肿瘤SUVmax大于5.0的特殊情况下,Menton 2011专家共识认为ΔSUVmax可能不可靠而首选Deauville评分。
- 采用Kaplan-Meier分析评估Menton 2011与ΔSUVmax对无进展生存期(PFS)的预后价值。
主要发现
- PET2时17%(100/581)患者按ΔSUVmax为PET阴性但按Menton 2011因残留SUVmax大于5.0被判为PET阳性;PET4时该比例为8%(49/581)。
- PET2阳性人群中,单纯ΔSUVmax的2年PFS为70%(范围58%-80%),而Menton 2011判为阳性者结局趋向更好,为81%(范围72%-87%)。
- 基线SUVmax低于10.0的10例患者按ΔSUVmax均为PET2阳性但按Menton 2011判为PET2阴性,其2年PFS与PET2阴性/PET4阴性患者相同,表明ΔSUVmax在此情况下产生假阳性结果。
关键数值与推荐
- Menton 2011标准结合ΔSUVmax,PET2截断值为66%,PET4截断值为70%,并结合Deauville量表。
- 基线SUVmax低于10.0或中期残留肿瘤SUVmax大于5.0时,Menton 2011专家共识认为ΔSUVmax可能不可靠,首选Deauville评分。
临床怎么用
- 作者推荐除基线SUVmax低于10.0的情况外,使用单纯ΔSUVmax而非Menton 2011标准评估弥漫性大B细胞淋巴瘤的中期代谢反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The GAINED phase 3 trial (ClinicalTrials.gov identifier: NCT01659099) evaluated a PET-driven consolidative strategy in patients with diffuse large B-cell lymphoma. In this post hoc analysis, we aimed to compare the prognostic value of the per-protocol PET interpretation criteria (Menton 2011 consensus) with the change in the SUVmax (ΔSUVmax) alone. Methods: Real-time central review of 18F-FDG PET/CT was performed in 581 patients after 2 cycles (PET2) and 4 cycles (PET4) of immunochemotherapy using the Menton 2011 criteria, combining the ΔSUVmax (cutoffs of 66% and 70% at PET2 and PET4, respectively) and the Deauville scale. In "special cases," when the baseline SUVmax was less than 10.0 or the interim residual tumor SUVmax was greater than 5.0, the Menton 2011 experts' consensus agreed that the ΔSUVmax may not be reliable and that the Deauville score is preferable. Prognostic values of Menton 2011 and ΔSUVmax were evaluated by Kaplan-Meier analyses in terms of progression-free survival (PFS). Results: Seventeen percent of patients at PET2 (100/581) and 8% at PET4 (49/581) had PET-negative results by ΔSUVmax but were considered to have PET-positive results according to Menton 2011 with residual SUVmax of greater than 5.0. For the population with PET2-positive results, 2-y PFS was 70% (range, 58%-80%) with ΔSUVmax alone, whereas the outcome tended to be better for those who were considered to have PET-positive results by Menton 2011, 81% (range, 72%-87%). Conversely, all 10 patients with baseline SUVmax of less than 10.0 had PET2-positive results by ΔSUVmax but were considered to have PET2-negative results by Menton 2011. These patients had the same 2-y PFS as patients with PET2-negative/PET4-negative results, indicating that the ΔSUVmax yielded false-positive results in this situation. Conclusion: We recommend the use of the ΔSUVmax alone rather than the Menton 2011 criteria for assessing the interim metabolic response in patients with diffuse large B-cell lymphoma, except when the baseline SUVmax is less than 10.0.
引用
- Itti E, Blanc-Durand P, Berriolo-Riedinger A, et al. Validation of the ΔSUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial. J Nucl Med. 2023. PMID: 37734837. doi:10.2967/jnumed.123.265871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。